Wyeth

Medimmune Limited

Millennium Pharmaceuticals Limited

Janssen Sciences Ireland Uc

Davinder Gill

Lioudmila Tchistiakova

David C Lowe

Viia Valge-Archer

Geertruida Machteld Veldman

Ralph Raymond Minter

Jing Li

Lynette A Fouser

Angela Widom

Caroline S Russell

Suzanne E Cohen

Albert George Thom

Ming Diana Qian

Nitin Krishnaji Damle

Kimberly Ann Marquette

Arthur Kunz

Erwin R Boghaert

Kiran Khandke

Philip Ross Hamann

John L Knopf

Samuel Goldman

Debra D Donaldson

Xiang-Yang Tan

James Callaway

Jack Steven Jacobsen

Deborah A Young

Ivan Lieberburg

Marion T Kasaian

Michael Grundman

Laird Bloom

Ronald Black

Yulia Vugmeyster

Lars Ekman

Macy X Jin

Bruce Jacobson

Keith M Gregg

Kodangattil R Sreekumar

Wagner Marcelo Zago

Gillian A Kingsbury

Margot O'Toole

Martine Jandrot-Perrus

Jean-Luc Villeval

Maya Arai

William Vainchencker

Samatha J Busfield

Gene G Kinney

Sreekumar R Kodangattil

Xiang Yang Tan

Seongeun Cho

Sadhana Jain

Amy Arlene Weaver

Karissa K Adkins

Heath M Guay

Manuel J Buttini

Kodangattil Raman Sreekumar

Lioudmile Tchistiakova

An immunogenic composition effective for eliciting an immune response against cells that present coronavirus S protein and/or coronavirus M protein derived antigens on a virus-like-particle (VLP) system. In a method embodiment, the antigen presenting VLP is administered to a mammal, such as a human, to elicit an immune response against coronavirus S protein and/or coronavirus M protein. A preferred method embodiment may include at least one additional dose of immunogenic composition to enhance the immune response effectiveness of the coronavirus vaccine.

Coronavirus vaccine and methods of use thereof

Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.

Anti-5T4 antibodies and uses thereof

The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.

Immunotherapy regimes dependent on ApoE status

The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered is monitored by measuring levels of tau.

Use of tau to monitor immunotherapy

The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.

Nucleic acid encoding antibody to human IL-22

Antibodies to human IL-22

The present invention provides binding proteins and antigen-binding fragments thereof, including human antibodies, that specifically bind to the human interleukin-21 receptor (IL-21R), and methods of using them. The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing, treating, and/or preventing IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, and other immune system disorders.

Methods of treatment utilizing binding proteins of the interleukin-21 receptor

The present invention provides binding proteins and antigen-binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing and/or treating IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders.

Interleukin-21 receptor binding proteins

Agents (e.g., antibodies and fragments thereof) that bind specifically to IL 13 and modulate the ability of IL-13 to interact with IL-13 receptors and signaling mediators are disclosed.

Nucleic acids encoding IL-13 binding agents

Antibodies against human IL-22 and uses therefor

The present invention provides monoclonal antibodies for human TrkB. In certain embodiments the inventive antibodies bind and activate human TrkB. In certain embodiments the inventive antibodies are selective for human TrkB in that they do not bind (or activate) human TrkA or human TrkC. In some embodiments the inventive monoclonal antibodies cross-react with murine TrkB. Humanized or veneered versions of the inventive antibodies are also encompassed. Pharmaceutical compositions that comprise inventive antibodies are provided as are methods for preparing the inventive antibodies and methods of using these for treatment, detection or purification purposes.

Anti-TrkB monoclonal antibodies and uses thereof

The invention provides isolated nucleic acid molecules and polypeptide molecules that encode glycoprotein VI, a platelet membrane glycoprotein that is involved platelet-collagen interactions. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

Glycoprotein VI and uses thereof

Growing community of inventors

Andover, MA, United States of America

Davinder Gill